This article is more than 5 years old. Information may no longer be current.

Inspire ups production of AzaSite during erythromycin ophthalmic ointment shortage

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DURHAM, N.C. — In response to the U.S. Food and Drug Administration's announcement of a manufacturing supply shortage of erythromycin ophthalmic ointment, Inspire Pharmaceuticals has announced plans to increase production of AzaSite.

Based on pharmacology and gonococcal microbiologic sensitivity data, the Centers for Disease Control and Prevention has recommended AzaSite (1% azithromycin ophthalmic solution) as an adequate alternate for neonatal prophylaxis use when erythromycin ophthalmic ointment is not available.

AzaSite has not been approved by the FDA for prophylaxis of ophthalmia neonatorum.

Visit the CDC, FDA and American Academy of Ophthalmology Web sites for additional updates regarding the shortage.